GPC Biotech licenses reverse genomics technology from ARIAD.
LeadCode is a proprietary drug-target interaction screening technology developed by GPC Biotech that can be applied across a broad range of compounds and disease areas. It is part of the company's Reverse Genomics platform, which is focused on addressing bottlenecks at later stages of the drug discovery process and uses discovery technologies to understand how drugs impact the body to improve drug design. LeadCode enables biopharmaceutical companies to effectively leverage existing product portfolios and reduce attrition of drug discovery programs. The technology is designed to identify and analyze the interaction of a small molecule, such as a drug, with the full complement of human proteins. LeadCode can define the mechanism-of-action of a particular molecule and identify possible toxic effects, which are critical to understanding that compound's potential as an effective treatment for a specific disease.
GPC Biotech will be applying LeadCode to its internal drug discovery and development efforts, as well as commercializing the technology for use by the biopharmaceutical industry. On January 31, 2003, GPC Biotech announced its first alliance using LeadCode. That collaboration is with Eli Lilly and company to elucidate the mechanism-of-action of a class of compounds that Lilly is developing in the area of metabolic diseases.
GPC Biotech AG is a biotechnology company dedicated to discovering and developing new anticancer drugs through innovative discovery technologies and development approaches. The company's lead product candidate -- satraplatin -- has successfully completed Phase 2 clinical trials and is expected to enter Phase 3 registrational studies during 2003. The company is leveraging its drug discovery technologies in novel ways to elucidate the mechanisms-of-action of drug candidates and to support the growth of its drug pipeline. Drug discovery and development alliance partners include: ALTANA Pharma of ALTANA AG, Aventis Pharma, Boehringer Ingelheim International GmbH, Eli Lilly and Company, MorphoSys AG, PanTherix Ltd., and Spectrum Pharmaceuticals, Inc.
GPC Biotech AG +49 (0)89 8565-2600 www.gpc-biotech.com
|Printer friendly Cite/link Email Feedback|
|Comment:||GPC Biotech licenses reverse genomics technology from ARIAD.|
|Publication:||BIOTECH Patent News|
|Date:||Feb 1, 2003|
|Previous Article:||Celgene expands kinase patent estate.|
|Next Article:||University of Nebraska obtains United States patent.|